Adult Drug Development Unit The Royal Marsden Hospital and The Institute of Cancer Research London UK

Belgium Federal Agency for Medicines and Health Products EUROSTATION Brussels Belgium

Boehringer Ingelheim Pharma GmbH and Co KG TA Oncology Biberach Germany

Centre for English Language Teaching University of York York UK

Centre Léon Bérard and University Claude Bernard Lyon 1 Lyon

Create for Chloe and UK Representative for aPODD European Medicines Agency London UK

Department of Clinical Research Gustave Roussy Villejuif and Paris Sud University Le Kremlin Bicêtre France

Department of Oncology for Children and Adolescents Gustave Roussy Cancer Campus Villejuif France

Drug Development Department Gustave Roussy Villejuif and University Paris Sud Orsay France

Gritstone Oncology Inc Emeryville USA

Imagine for Margo Fourqueux France

Jeunes Solidarité Cancer Paris France

Novartis AG Basel Switzerland

Paediatric and Adolescent Drug Development Team Oak Centre for Children and Young People The Royal Marsden Hospital and The Institute of Cancer Research London UK

Paediatric and Adolescent Drug Development Team Oak Centre for Children and Young People The Royal Marsden Hospital and The Institute of Cancer Research London UK; Universitair Ziekenhuis Antwerpen Edegem Belgium

Paediatric Haematology Oncology Clinical Research Paediatric Drug Development University Childreńs Hospital 3 Hufelandstraße Essen Germany

Pediatric Oncology Department University Hospital Brno School of Medicine Masaryk University Brno Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute ICRC Brno St Anna University Hospital Brno Czech Republic

Pharmaceuticals Division PDOA Oncology F Hoffmann La Roche Ltd Basel Switzerland

PODD Foundation City Point London UK

Product Development Scientific Support Department European Medicines Agency London UK

Regulatory Strategy Oncology Pfizer Italia Milano Italy

Zobrazit více v PubMed

Vassal G, Rousseau R, Blanc P. et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur J Cancer 2015; 51(2): 218–224. PubMed

Pearson ADJ, Herold R, Rousseau R. et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. Eur J Cancer 2016; 62: 124–131. PubMed

ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001; 47(1): 45–50. PubMed

Veal GJ, Hartford CM, Stewart CF.. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 2010; 28(32): 4790–4799. PubMed PMC

Lee DP, Skolnik JM, Adamson PC.. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol 2005; 23(33): 8431–8441. PubMed

Paoletti X, Geoerger B, Doz F. et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults’ trials. Eur J Cancer 2013; 49(10): 2392–2402. PubMed

Meinhardt A, Burkhardt B, Zimmermann M. et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. JCO 2010; 28(19): 3115–3121. PubMed

Hoffman LM, Gore L.. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 2014; 4:63. PubMed PMC

Merchant MS, Wright M, Baird K. et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 2016; 22(6): 1364–1370. PubMed PMC

Geoerger B, Fox E, Pappo AS. et al. Pembrolizumab in Pediatric Patients with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed, or Refractory Solid Tumor or Lymphoma: Phase I/II KEYNOTE-051 Study. Dublin: SIOP; 2016. PubMed

DuBois SG, Shusterman S, Ingle AM. et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study. Clin Cancer Res 2011; 17(15): 5113–5122. PubMed PMC

Momper JD, Mulugeta Y, Green DJ. et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr 2013; 167(10): 926.. PubMed

White-Koning M, Civade E, Geoerger B. et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 2011; 17(14): 4862–4871. PubMed

Beaver JA, Ison G, Pazdur R.. Reevaluating eligibility criteria—balancing patient protection and participation in oncology trials. N Engl J Med 2017; 376(16): 1504–1505. PubMed

Chawla S, Henshaw R, Seeger L. et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14(9): 901–908. PubMed

Olmos D, Postel-Vinay S, Molife LR. et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11(2): 129–135. PubMed PMC

Pappo AS, Vassal G, Crowley JJ. et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 2014; 120(16): 2448–2456. PubMed PMC

LoRusso PM, Rudin CM, Reddy JC. et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17(8): 2502–2511. PubMed PMC

Robinson GW, Orr BA, Wu G. et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium studies PBTC-025B and PBTC-032. J Clin Oncol 2015; 33(24): 2646–2654. PubMed PMC

Kool M, Jones DTW, Jäger N. et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014; 25(3): 393–405. PubMed PMC

Fern LA, Lewandowski JA, Coxon KM, Whelan J.. National Cancer Research Institute Teenage and Young Adult Clinical Studies Group, UK. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol 2014; 15(8): e341–e350. PubMed

Tacher V, Le Deley M-C, Hollebecque A. et al. Factors associated with success of image-guided tumour biopsies: results from a prospective molecular triage study (MOSCATO-01). Eur J Cancer 2016; 59: 79–89. PubMed

Stark D, Bielack S, Brugieres L. et al. Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project. Eur J Cancer Care (Engl) 2016; 25(3): 419–427. PubMed

Chuk MK, Mulugeta Y, Roth-Cline M. et al. Enrolling adolescents in disease/target-appropriate adult oncology clinical trials of investigational agents. Clin Cancer Res 2017; 23(1): 9–12. PubMed PMC

He N. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Eur J Health Law 2008; 15: 223–250. PubMed

Lepola P, Needham A, Mendum J. et al. Informed Consent for Paediatric Clinical Trials in Europe 2015ropean Network For Paediatric Reearch At the European Medical Agency [on-line]; http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/12/WC500199234.pdf (16 January 2018, date last accessed).

REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf (16 January 2018, date last accessed).

Fanale MA, Forero-Torres A, Rosenblatt JD. et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18(1): 248–255. PubMed

Ansell SM, Lesokhin AM, Borrello I. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372(4): 311–319. PubMed PMC

Bleyer A, O’Leary M, Barr R, Ries LAG. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute (NIH Pub No 06-5767) 2006.

Spain L, Julve M, Larkin J.. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert Opin Pharmacother 2016; 17(7): 1031–1038. PubMed